Biosimilars Add “Urgency” To Medicare Payment Reforms – MedPAC Commissioner
Developing alternatives to the ASP-based reimbursement system for Medicare Part B drugs may become increasingly important to ensure the program will benefit from lower-cost biosimilars, Georgetown’s Jack Hoadley points out.
You may also be interested in...
MedPAC will analyze alternatives for Medicare Part B to use “least costly alternative” payment method in lieu of legislative authority; OIG says Part B dispensing fees are too high; PCORI releases draft proposal on research review.
The bundled payment pilot program resulted in a 34% decrease in overall cancer treatment costs among participating medical centers despite a 179% increase in drug spending, according to results released July 8.
Ophthalmologists are among the highest billing specialties listed in the Medicare Part B physician payment data, with Genentech’s Lucentis a strong driver of cost.